Acetylcholine
- Generic Name
- Acetylcholine
- Brand Names
- Miochol
- Drug Type
- Small Molecule
- Chemical Formula
- C7H16NO2
- CAS Number
- 51-84-3
- Unique Ingredient Identifier
- N9YNS0M02X
- Background
A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
- Indication
Used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.
IMUNON's DNA Vaccine Shows Promising Immune Response Against COVID-19 in Phase 1 Trial
• IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.
• The PlaCCine® technology-based vaccine showed cross-reactivity against multiple COVID-19 variants and maintained stability at workable temperatures for up to one year.
• The trial involving 24 healthy volunteers confirmed IMNN-101's safety profile with no serious adverse effects, positioning it as a potential alternative to current mRNA vaccines.
TYRA-300 Phase 2 Trial for Non-Muscle Invasive Bladder Cancer Gets FDA Green Light
• The FDA has cleared Tyra Biosciences' IND application for TYRA-300, allowing a Phase 2 trial in low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).
• The SURF302 trial will evaluate the safety and efficacy of TYRA-300, an oral FGFR3-selective inhibitor, in patients with FGFR3-altered NMIBC.
• The open-label study will enroll up to 90 patients, with the primary endpoint being the complete response rate at 3 months, with patient dosing expected in Q2 2025.
• TYRA-300 is also being investigated in metastatic urothelial carcinoma (mUC) and pediatric achondroplasia, showing promising initial efficacy and tolerability.
UGN-102 Demonstrates Durable Response in Recurrent Low-Grade Bladder Cancer
• UroGen Pharma's UGN-102 shows an 82.3% duration of response at 12 months in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC).
• The Phase 3 ENVISION trial highlights a 79.6% complete response rate at 3 months following the initial UGN-102 instillation, indicating a promising treatment for LG-IR-NMIBC.
• UGN-102's safety profile remains consistent with previous trials, reinforcing its potential as a valuable option for patients facing repeated surgical interventions.
• The FDA has set a PDUFA goal date of June 13, 2025, for UGN-102, potentially marking it as the first FDA-approved treatment for LG-IR-NMIBC.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath